Skip to main content
OpenTrials

Clinical trial condition

Hereditary Complement Deficiency Diseases

Explore clinical trials studying Hereditary Complement Deficiency Diseases. Study availability and eligibility vary by location and protocol.

145 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Hereditary Complement Deficiency Diseases trial results

Completed

A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

NCT05147181

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów/Szpital w Poznaniu Poznan, Greater Poland Voivodeship, Poland
  • Szpital Uniwersytecki nr 2 Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
  • Szpital Uniwersytecki w Krakowie Krakow, Lesser Poland Voivodeship, Poland
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu Wroclaw, Lower Silesian Voivodeship, Poland
View all 14 locations
View Trial Details
Completed

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

NCT06467084

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • KalVista Investigative Site Birmingham, Alabama, United States
  • KalVista Investigative Site Scottsdale, Arizona, United States
  • KalVista Investigative Site San Diego, California, United States
  • KalVista Investigative Site Santa Monica, California, United States
View all 24 locations
View Trial Details
Completed

A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

NCT06346899

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • The First Affiliated Hospital of Fujian Medical University Fuzhou, Fujan, China
  • The First Affiliated Hospital ,Sun Yat-sen University Guangzhou, Guangdong, China
  • The Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China
  • Henan Provincial People's Hospital Zhengzhou, Henan, China
View all 13 locations
View Trial Details
Completed

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT04618211

Conditions
Angioedema, Angioedemas, Hereditary, C1 Esterase Inhibitor Deficiency, +23 more
Locations
  • Study site Birmingham, Alabama, United States
  • Study site Paradise Valley, Arizona, United States
  • Study site San Diego, California, United States
  • Study site Santa Monica, California, United States
View all 36 locations
View Trial Details
Completed

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779

Conditions
Angioedema, Angioedemas, Hereditary, C1 Esterase Inhibitor Deficiency, +27 more
Locations
  • Study Site Birmingham, Alabama, United States
  • Study Site Paradise Valley, Arizona, United States
  • Study Site Little Rock, Arkansas, United States
  • Study Site San Diego, California, United States
View all 76 locations
View Trial Details
Completed

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

NCT04130191

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • Medical University of Vienna Vienna, Austria
  • Klinikum der Johann-Wolfgang Goethe-Universitat Frankfurt am Main, Hesse, Germany
  • Charité - Universitätsmedizin Berlin Berlin, Germany
  • Universitatsklinikum Dusseldorf Düsseldorf, Germany
View all 19 locations
View Trial Details
Completed

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185

Conditions
Angioedema, Angioedemas, Hereditary, C1 Esterase Inhibitor Deficiency, +23 more
Locations
  • Study site Birmingham, Alabama, United States
  • Study site Paradise Valley, Arizona, United States
  • Study site St Louis, Missouri, United States
  • Study Site Vienna, Austria
View all 19 locations
View Trial Details

Related conditions